Red Flags Detected

  • Auditor Change (new) — KPMG replaced Deloitte as auditor in 2025 after Deloitte served since 2015; no explanation provided for the change.
NASDAQ: SGMT Sagimet Biosciences Inc. 10-K

Sagimet pivots MASH strategy to F4 combination trial, advances TVB-3567; Phase 3 monotherapy fate unclear

Filed March 11, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 12, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade SGMT commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

View original filing on SEC.gov View full financials on EDGAR ↗

Generated by AI · Jun 5, 2026 4:15 AM